
Nicotine Is in Unchartered Territory
But in 2025, nicotine isn't so straightforward. Smoking is so deadly not because of nicotine, per se, but because of tobacco: Lighting a cigarette burns tobacco, releasing nicotine into the body. Chewing tobacco entails gnawing on actual tobacco leaves. Nowadays, it's easier than ever to get a nicotine buzz without any tobacco at all: Just puff on a vape or pop a tiny nicotine pouch between your teeth and upper lip. These cigarette alternatives have been around for a while, but only recently have they gone fully mainstream. In January, the FDA officially sanctioned the sale of Zyn, among the most recognizable nicotine-pouch brands. In the past three months alone, Philip Morris International, which makes Zyn, shipped 190 million cans of the stuff to stores. And last month, the agency reversed a prior ruling and authorized Juul e-cigarettes. These products, the FDA has concluded, 'generally have lower health risks than cigarettes.'
In this nicotine boom, it's easy to see the drug as harmless, even good for you. Ads that tout the benefits of nicotine are everywhere: Zyn, for example, has been marketed as an 'office essential' that also offers 'relaxation on-the-go.' Nicotine somehow feels both energizing and relaxing at the same time, kind of like the buzz of a vodka Red Bull. The drug has been linked to statistically significant improvements in a number of cognitive exercises. The marketing goes further: Joe Rogan has hawked Athletic Nicotine, a nicotine-pouch brand that claims the drug can serve as an 'exercise performance-enhancing tool.' Tucker Carlson—who has his own brand of nicotine pouches—recently claimed that because of nicotine, he is 'never sick.'
But nicotine is not a wonder drug. The cognitive improvements found in studies were modest. Bethea AnnaLouise Kleykamp, an assistant professor of psychiatry at the University of Maryland who has studied nicotine, summed it up this way: The drug 'might be, if you were to subtract it from the smoke, something that could help some people,' such as those who are sleep-deprived or have a cognitive disorder like ADHD. Not exactly a ringing endorsement. Moreover, there's still a lot we don't know about what nicotine alone does to the body.
All of this has nicotine in a strange place. Before the advent of newer products, the field of public health was united in its stance that no one should be using cigarettes, and thus nicotine. Now the message is more muddled than ever.
Some public-health experts still suggest staying away from nicotine in and of itself. After the decades-long war against smoking, they see new products as Big Tobacco's latest gambit to hook the public. Others make a different calculation: If the health effects of nicotine alone are less concerning than those of cigarettes, what's so bad about an adult sucking on a Zyn? Presuming people recognize that these products 'may have some health risks,' Neal Benowitz, an emeritus professor of medicine at UC San Francisco, told me, 'I have no problem with that.'
Such differing views stem from the unclear health effects of cigarette alternatives. Consuming nicotine via vape or pouch is surely safer than smoking a cigarette, but that isn't saying much. No researchers I spoke with gave nicotine an unequivocal endorsement. 'I would never go so far as to say that any drug is completely safe,' Jed Rose, an emeritus professor of psychiatry at Duke University who runs a research firm that has done paid research for nicotine companies, told me. 'Whether nicotine contributes in any way to other diseases associated with smoking is not as firmly resolved as people like to think.'
Rose cited a study that showed nicotine accelerated tumor growth in mice. Other experts I spoke with cited data from Sweden demonstrating that smokeless products carry some cardiovascular risks. And emerging research indicates that the components inside of vapes can leach heavy metals into the mist that users inhale, potentially exposing them to increased cancer risk. For the most part, science simply hasn't answered the question of how bad nicotine alone is for you. Most of the studies on the bodily effects of nicotine have been completed using subjects who smoke.
For now, the clearest problem with puffing on a Juul is that nicotine remains extremely addictive, whatever form it comes in. Addiction researchers have said that nicotine is just as difficult to quit as heroin. Smokeless products might be a little easier to quit than cigarettes, based on how they deliver nicotine. But it's reasonable to assume that these new products will also worsen the problem of nicotine addiction by making the drug easier to consume. Desk workers can pop nicotine pouches without having to step away for a smoke break. Vape clouds are more readily concealed than the stench of cigarette smoke. This is part of the appeal: Rogue, a Zyn competitor, advertises its product as a way to 'enjoy the nicotine you love without getting noticed, whether you're in a marathon of meetings, perfecting your meal-prep, or just can't step away for a smoke break.' (Rogue, like other nicotine brands, has to legally include warnings in its ads that its products are addictive.)
The effects of an addiction alone are not typically a first-order concern in the world of public health. Addictions typically come with other, more pressing consequences: For cigarettes, it's heart attacks and cancer; for heroin, it's overdoses. Anyone who has seen photos of smokers hooked to oxygen or revealing their lung-cancer scars can attest that public health has become expert in warning potential victims of these types of health problems. The risks of a nicotine addiction without the smoke are murkier. 'There are interpersonal, intrapersonal, and economic consequences to being addicted,' Eric Donny, a neuroscience professor at Wake Forest University who studies nicotine, told me. 'It's really hard to quantify this in a way that we are used to.'
Nicotine boosters have compared the drug to caffeine—which is also addictive, but generally not a problem. (Hence the Death Before Decaf shirts, tote bags, and even tattoos.) But research suggests that nicotine addiction is more intense than a caffeine dependency, potentially taking a bigger toll on people's lives. The financial costs alone can be onerous: Nicotine prices vary a lot from state to state, but in Washington, D.C., where I live, someone with an extreme Zyn habit may be shelling out upwards of $10 a day to feed their addiction. A Juul isn't much cheaper. With either product, a heavy user is likely to spend several thousands of dollars a year.
Addiction can also take a psychological toll. Being hooked on nicotine means your brain is always screaming for another hit of the drug. At times, the longing can feel insatiable, and can force people to act in ways that are entirely against their own self-interest. A teen addicted to vaping might take a few puffs in the school bathroom, even if getting caught might mean a suspension. Or a longtime user may continue to pop nicotine pouches after a heart attack, despite research showing that quitting nicotine significantly reduces someone's risk of death.
These downsides might seem minuscule compared with those of cigarettes. A rotting lung is considerably worse than a $10-a-day nicotine habit. But they shouldn't be ignored. If cigarette-smoking rates continue their decades-long drop, it's reasonable to assume that vaping and pouches will become the dominant ways people consume nicotine. New nicotine products might have solved the biggest problem with smoking. Many other, more subtle problems still remain.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Associated Press
32 minutes ago
- Associated Press
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
35 minutes ago
- Yahoo
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults1 This approval marks an important step in expanding the impact of AJOVY beyond adults since its U.S. approval in 2018, and underscores Teva's ongoing efforts to advance and address neurological challenges2 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine. Preventative treatment can help reduce the frequency of migraine attacks, helping children and adolescents to better manage the condition day-to-day. AJOVY is administered once a month and available for in-office or at home use, offering a treatment option that is intended to support adherence and reduce treatment burden for families.1 'Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood,' said Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva. 'With this FDA approval, AJOVY now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.' 1 in 10 children and adolescents in the U.S. suffer from migraine, one of the most common and disabling neurological conditions.3 Despite its widespread prevalence, pediatric migraine is often underrecognized and undertreated, contributing to missed school days, difficulties with schoolwork, and disrupted social activities.4 "Pediatric migraine is a complex condition that can significantly impact a child's daily life, from school performance to emotional well-being," said Dr. Jennifer McVige, MD, MA, Pediatric Neurologist at the DENT Neurologic Institute. 'Having an FDA-approved treatment like AJOVY offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.' Building on its established success in adult patients since its U.S. approval in 2018, this expanded indication strengthens Teva's commitment to broadening access to neuroscience therapies across age groups.2 AJOVY continues to demonstrate efficacy in addressing the underlying biology of migraine and now provides a treatment pathway for a patient population with historically limited preventive options. About MigraineMigraine attacks cause disabling pain, nausea, vomiting and sensitivities to light and sound, resulting in serious effects on the ability to complete daily tasks.5 Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.3 About AJOVYAJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit INDICATION AND USAGE AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. IMPORTANT SAFETY INFORMATION Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting. Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted. Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. AJOVY should be discontinued if signs or symptoms of Raynaud's phenomenon develop. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions. Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescents; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. Al Khalili Y, Asuncion RMD, Chopra P. Migraine Headache in Childhood. [Updated 2023 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Christopher J L Murray, Kanyin Liane Ong, Valery L Feigin, Theo Vos, and Tarun Dua on behalf of the GBD network. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. (in press). Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations InquiresTevaIR@